MedTrace Logo

Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

NCT00027989 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-12-18

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of combining liposomal doxorubicin with gemcitabine in treating women who have metastatic breast cancer.

Conditions

Interventions

DRUG

gemcitabine hydrochloride

DRUG

pegylated liposomal doxorubicin hydrochloride

Sponsors & Collaborators

  • Pharmatech Oncology

    lead INDUSTRY

Principal Investigators

  • Sandy Marcus · Pharmatech Oncology

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00027989 on ClinicalTrials.gov